Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Treatment Period	STARTED	Rivaroxaban (Xarelto, BAY59-7939)	1,731
Treatment Period	STARTED	Enoxaparin/VKA	1,718
Treatment Period	Participants Received Treatment	Rivaroxaban (Xarelto, BAY59-7939)	1,718
Treatment Period	Participants Received Treatment	Enoxaparin/VKA	1,711
Treatment Period	COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	1,426
Treatment Period	COMPLETED	Enoxaparin/VKA	1,367
Treatment Period	NOT COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	305
Treatment Period	NOT COMPLETED	Enoxaparin/VKA	351
Observational Period	STARTED	Rivaroxaban (Xarelto, BAY59-7939)	1,425
Observational Period	STARTED	Enoxaparin/VKA	1,407
Observational Period	COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	1,380
Observational Period	COMPLETED	Enoxaparin/VKA	1,369
Observational Period	NOT COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	45
Observational Period	NOT COMPLETED	Enoxaparin/VKA	38

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00440193/flow